ArticlePloS one2014
Striatal dopamine D2/3 receptor availability in treatment resistant depression.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- Treatment-resistant depression: molecular mechanisms and management.Molecular biomedicine · 2024Review
- Prenatal dexamethasone exposure alters effort decision making and triggers nucleus accumbens and anterior cingulate cortex functional changes in male rats.Translational psychiatry · 2022Article
- Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?Frontiers in pharmacology · 2022Review
- Striatal dopamine deficits predict reductions in striatal functional connectivity in major depression: a concurrentTranslational psychiatry · 2018Article
- Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [Biological psychiatry · 2018Article
- The relationship between the dopaminergic system and depressive symptoms in cervical dystonia.European journal of nuclear medicine and molecular imaging · 2017Article
- Dextroamphetamine and Pramipexole Combination for Treatment-Resistant Unipolar Depression.Psychiatric annals · 2016Article
- Correction: Striatal Dopamine D2/3 Receptor Availability in Treatment Resistant Depression.PloS one · 2015Article
- Neurobiology of Chronic Stress-Related Psychiatric Disorders: Evidence from Molecular Imaging Studies.Chronic stress (Thousand Oaks, Calif.)Article
Corrections and comments
- Erratum issuedCorrection: Striatal Dopamine D2/3 Receptor Availability in Treatment Resistant Depression.2015 · Ruhé, Eric H G [corrected to Ruhé, Henricus G]
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D(2/3) receptor (D2/3R) binding has not been investigated in TRD subjects. We used [(123)I]IBZM single photon emission computed tomography (SPECT) to investigate striatal D2/3R binding in TRD. We included 6 severe TRD patients, 11 severe TRD patients on antipsychotics (TRD AP group) and 15 matched healthy controls. Results showed no significant difference (p = 0.75) in striatal D2/3R availability was found between TRD patients and healthy controls. In the TRD AP group D2/3R availability was significantly decreased (reflecting occupancy of D2/3Rs by antipsychotics) relative to TRD patients and healthy controls (p<0.001) but there were no differences in clinical symptoms between TRD AP and TRD patients. This preliminary study therefore does not provide evidence for large differences in D2/3 availability in severe TRD patients and suggests this TRD subgroup is not characterized by altered dopaminergic transmission. Atypical antipsychotics appear to have no clinical benefit in severe TRD patients who remain depressed, despite their strong occupancy of D2/3Rs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.